289 related articles for article (PubMed ID: 18972276)
21. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
[TBL] [Abstract][Full Text] [Related]
22. Effects of budesonide/formoterol combination therapy versus budesonide alone on airway dimensions in asthma.
Hoshino M; Ohtawa J
Respirology; 2012 May; 17(4):639-46. PubMed ID: 22248352
[TBL] [Abstract][Full Text] [Related]
23. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
24. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol.
Pavord ID; Jeffery PK; Qiu Y; Zhu J; Parker D; Carlsheimer A; Naya I; Barnes NC
J Allergy Clin Immunol; 2009 May; 123(5):1083-9, 1089.e1-7. PubMed ID: 19368965
[TBL] [Abstract][Full Text] [Related]
25. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
[TBL] [Abstract][Full Text] [Related]
27. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
[TBL] [Abstract][Full Text] [Related]
28. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease.
Cazzola M
Pulm Pharmacol Ther; 2006; 19(2):79-89. PubMed ID: 15964228
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
30. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
[TBL] [Abstract][Full Text] [Related]
31. ADRB2 polymorphisms and budesonide/formoterol responses in COPD.
Bleecker ER; Meyers DA; Bailey WC; Sims AM; Bujac SR; Goldman M; Martin UJ
Chest; 2012 Aug; 142(2):320-328. PubMed ID: 22383665
[TBL] [Abstract][Full Text] [Related]
32. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
Kaiser H; Parasuraman B; Boggs R; Miller CJ; Leidy NK; O'Dowd L
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):295-303. PubMed ID: 18814453
[TBL] [Abstract][Full Text] [Related]
33. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
[TBL] [Abstract][Full Text] [Related]
34. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.
Cazzola M; Santus P; Di Marco F; Carlucci P; Mondoni M; Matera MG; Centanni S
Pulm Pharmacol Ther; 2004; 17(3):121-5. PubMed ID: 15123220
[TBL] [Abstract][Full Text] [Related]
35. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
36. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
[TBL] [Abstract][Full Text] [Related]
38. [Budesonide/formoterol in the treatment of COPD].
Peces-Barba Romero G; Villar Alvarez F
Arch Bronconeumol; 2010; 46 Suppl 4():22-7. PubMed ID: 20850023
[TBL] [Abstract][Full Text] [Related]
39. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory and functional effects of increasing asthma treatment with formoterol or double dose budesonide.
Menezes MB; Teixeira AL; Terra Filho J; Vianna EO
Respir Med; 2008 Oct; 102(10):1385-91. PubMed ID: 18632258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
